Exenatide vs Peptide YY
Research Verdict
Exenatide is the stronger research reference for the stated comparison criteria. Exenatide: FDA approved (Byetta 2005, Bydureon 2012), multiple Phase 3 RCTs, EXSCEL CVOT.
Quick Answers
Which is better, Exenatide or Peptide YY?
Exenatide is the stronger research reference for the stated comparison criteria. Exenatide: FDA approved (Byetta 2005, Bydureon 2012), multiple Phase 3 RCTs, EXSCEL CVOT.
What is the key difference between Exenatide and Peptide YY?
Exenatide is a GLP-1 receptor agonist with glucose-dependent insulin secretion; PYY is an endogenous satiety hormone acting via Y2 receptors - different mechanisms for appetite regulation, with PYY development stalled by tolerability issues.
Evidence Comparison
Exenatide: FDA approved (Byetta 2005, Bydureon 2012), multiple Phase 3 RCTs, EXSCEL CVOT. Peptide YY: human infusion studies (Batterham 2002, 2003 NEJM) showing appetite suppression, but no approved formulation, significant nausea at effective doses limiting development. Exenatide vastly stronger on clinical evidence.
Evidence Context Favoring Exenatide
Any clinical or translational research context - exenatide has the approved formulation and established safety profile.
Evidence Context Favoring Peptide YY
Basic research into Y2 receptor-mediated satiety signaling or endogenous appetite hormone biology.
Side-by-Side Snapshot
| Evidence grade | Exenatide: Level A Peptide YY: Level C |
|---|---|
| Research status | Exenatide: FDA Approved Peptide YY: Phase 1 |
| Primary category | Exenatide: Weight Loss & Metabolic Peptide YY: Weight Loss & Metabolic |
| Cited studies | Exenatide: 3 Peptide YY: 2 |